Company Monitoring Page for Daiichi-Sankyo

latest headlines for company on cafepharma

Seagen wins future royalties in Enhertu patent dispute
Pharmaphorum
Wed, 10/18/23 - 10:07 am
Tags:
Seagen, Daiichi Sankyo, breast cancer, Enhertu, drug royalties
BioNTech takes another leaf out of Daiichi playbook, paying $70M for HER3-directed ADC
Fierce Biotech
Thu, 10/12/23 - 10:07 am
Tags:
BioNTech, Daiichi Sankyo, antibody-drug conjugate, breast cancer
Daiichi Sankyo reports positive results from trial of breast cancer therapy
Clinical Trials Arena
Mon, 09/25/23 - 11:47 am
Tags:
Daiichi Sankyo, clinical trials, Dato-DXd, breast cancer
AstraZeneca, Daiichi Tout Phase III Breast Cancer Data in Challenge to Gilead
BioSpace
Fri, 09/22/23 - 11:51 am
Tags:
AstraZeneca, Daiichi Sankyo, breast cancer, antibody-drug conjugate, clinical trials
AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind
Fierce Biotech
Tue, 09/12/23 - 12:00 pm
Tags:
AstraZeneca, Daiichi Sankyo, antibody-drug conjugate, non-small cell lung cancer, Dato-DXd
The 10 highest value R&D projects in biopharma
Fierce Biotech
Wed, 09/6/23 - 10:17 am
Tags:
R&D, biotech, Merck, sotatercept, Daiichi Sankyo, AstraZeneca, Dato-DXd, Novo Nordisk, CagriSema, Eli Lilly, donanemab, Karuna Therapeutics, Zai Lab, KarXT, Moderna Therapeutics, mRNA-1647, Novartis, iptacopan, Madrigal Pharmaceuticals, resmetirom, Cytokinetics, aficamten, Roche, Chugai, tiragolumab
Daiichi Sankyo to close Japanese research and development subsidiary
Pharmaceutical Business Review
Tue, 08/8/23 - 10:17 am
Tags:
Daiichi Sankyo, Japan, R&D, RD Novare
Daiichi Sankyo will remain 'dominant' in ADC market for oncology treatments
Biopharma Reporter
Mon, 08/7/23 - 10:14 am
Tags:
Daiichi Sankyo, antibody drug conjugate, oncology, Seagen, Roche
Enhertu offers survival benefits in Phase II solid tumour trial
Clinical Trials Arena
Sat, 07/29/23 - 10:42 pm
Tags:
AstraZeneca, Daiichi Sankyo, Enhertu, clinical trials, solid tumors
FDA okays Daiichi Sankyo’s Vanflyta for first-line AML
Pharmaphorum
Fri, 07/21/23 - 10:08 am
Tags:
Daiichi Sankyo, Vanflyta, FDA, AML
AstraZeneca stock slides as pivotal lung cancer readout on Daiichi-partnered ADC spooks investors
Fierce Biotech
Mon, 07/3/23 - 11:40 am
Tags:
AstraZeneca, Daiichi Sankyo, antibody-drug conjugate, Enhertu, clinical trials, non-small cell lung cancer
ASCO 2023 – early first-line lung cancer data mined for datopotamab gold
EP Vantage
Wed, 06/7/23 - 10:02 am
Tags:
ASCO 2023, Daiichi Sankyo, AstraZeneca, datopotamab deruxtecan, non-small cell lung cancer
ASCO puts spotlight on advancing antibody-drug conjugate pipeline
BioPharma Dive
Thu, 05/25/23 - 08:51 pm
Tags:
ASCO 2023, antibody-drug conjugate, Merck, BioNTech, Daiichi Sankyo
2023’s biggest launches: the story so far
EP Vantage
Fri, 05/12/23 - 10:19 am
Tags:
drug launches, AbbVie, Almirall, Apellis Pharmaceuticals, Astellas, AstraZeneca, Biogen, CRISPR Therapeutics, Daiichi Sankyo, Eli Lilly, Genmab, GSK, Iveric Bio, Pfizer, Roche, SAGE Therapeutics, Sanofi, Sarepta Therapeutics, Shionogi, Swedish Orphan Biovitrum, Vertex Pharmaceuticals
A blockbuster year could be building
EP Vantage
Wed, 05/10/23 - 09:55 am
Tags:
AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Gilead Sciences, Horizon Therapeutics, Merck, Moderna Therapeutics, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche, Sanofi
FDA again delays Daiichi's plans to challenge Astellas and Novartis for blood cancer market
Fierce Biotech
Fri, 04/21/23 - 10:08 am
Tags:
Daiichi Sankyo, Astellas, Novartis, quizartinib, FDA, blood cancer
Go or no go? Seagen's Padcev eyes FDA approval
EP Vantage
Mon, 04/3/23 - 09:41 am
Tags:
FDA, AbbVie, Alvotech, Ascendis Pharma, Astellas, AstraZeneca, Biogen, Daiichi Sankyo, Eli Lilly, Ferring Pharmaceuticals, Hugel, Innoviva, Ionis Pharmaceuticals, Lundbeck, Merck, Novo Nordisk, Otsuka, Pfizer, Roche Seagen, Seres Therapeutics, Takeda, UCB, Vertex Pharmaceuticals
Esperion, Daiichi Sankyo milestone payment feud heats up with new lawsuit
Fierce Pharma
Tue, 03/28/23 - 10:57 pm
Tags:
Esperion Therapeutics, Daiichi Sankyo, Nexletol, SEC
Zymeworks, Daiichi end $293M bispecific collab after 6 unfruitful years
Fierce Biotech
Mon, 03/20/23 - 09:56 am
Tags:
Zymeworks, Daiichi Sankyo, immuno-oncology, biobucks
Daiichi torches Esperion’s Nexletol milestone promises
EP Vantage
Fri, 03/17/23 - 10:10 am
Tags:
Daiichi Sankyo, Esperion Therapeutics, Nexletol

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.